Modeling Benefits, Costs, and Affordability of a Novel Gene Therapy in Hemophilia A

The objective was to undertake an early cost-effectiveness assessment of valoctocogene roxaparvovec (valrox; Roctavian) compared to factor (F)VIII prophylaxis or emicizumab (Hemlibra; Roche HQ, Bazel, Switzerland) in patients with severe Hemophilia A (HA) without FVIII-antibodies. We also aimed to i...

Descripción completa

Detalles Bibliográficos
Autores principales: ten Ham, Renske M.T., Walker, Simon M., Soares, Marta O., Frederix, Geert W.J., Leebeek, Frank W.G., Fischer, Kathelijn, Coppens, Michiel, Palmer, Stephen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820916/
https://www.ncbi.nlm.nih.gov/pubmed/35141470
http://dx.doi.org/10.1097/HS9.0000000000000679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820916/
https://www.ncbi.nlm.nih.gov/pubmed/35141470
http://dx.doi.org/10.1097/HS9.0000000000000679

Ejemplares similares